Last reviewed · How we verify
INM176
At a glance
| Generic name | INM176 |
|---|---|
| Sponsor | Milton S. Hershey Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA (PHASE1, PHASE2)
- AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients (PHASE1)
- An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INM176 CI brief — competitive landscape report
- INM176 updates RSS · CI watch RSS
- Milton S. Hershey Medical Center portfolio CI